• Member Login
  • Become a Member
  • Database Search
IATI - Israel Advanced Technology Industries
IATI - Israel Advanced Technology Industries
IATI News & Events Daily Industry News IATI Biomed 2015: Japan-based Takeda readies strategic investment in Israel

IATI Biomed 2015: Japan-based Takeda readies strategic investment in Israel

May. 13, 2015

Japan-based Takeda Pharmaceuticals, the largest pharmaceutical company in Asia, is increasing efforts for strategic investments in Israel through Takeda Venture Investments (TVI), its Silicon Valley-based venture fund.

“I think there’s a unique set of conditions here in Israel that make it a great place for us to invest in innovation,” said Tetsuyuki Maruyama, who heads Takeda's research and development team in a Monday interview with The Jerusalem Post.

In 2013, Takeda launched a commercial subsidiary in Israel to market its pharmaceutical products, and the following year it helped establish FutuRx, a biotech accelerator, with the help of OrbiMed Israel Partners and Johnson & Johnson Innovation.

Though four companies have gone through FutuRx, which focuses generally on biotech, Takeda is now looking to fund promising seed companies that fit in with its strategic vision through TVI. It is currently doing diligence on several promising prospects, according to Michal Silverberg, TVI's Senior Director of External Innovation, who is based in Israel.

Maruyama has come to Israel to participate in the IATI Biomed conference, which in recent years has become one of the premier life sciences events in the world. “For me, it’s the most important one,” he said, adding that he generally skips other such conferences.

For the full interview on The Jerusalem Post click here.

| Terms of Use | Privacy Policy | Sitemap